autologous crispr-cas9 engineered tumor infiltrating lymphocytes ksq-001ex
Generic: Autologous CRISPR-Cas9 Engineered Tumor Infiltrating Lymphocytes KSQ-001EX
autologous crispr-cas9 engineered tumor infiltrating lymphocytes ksq-001ex: 1 clinical trial tracked.
autologous crispr-cas9 engineered tumor infiltrating lymphocytes ksq-001ex evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about autologous crispr-cas9 engineered tumor infiltrating lymphocytes ksq-001ex, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
Primary endpoint: Safety and adverse events (AEs)
Interventionalopen15 targetStarted 2024-01Completion 2029-011 site · United StatesM.D. Anderson Cancer Center